Cargando…

Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis

OBJECTIVE: It is unclear how the compounding prevalence of inflammatory bowel disease (IBD) has translated into the causes and rates of hospitalisation, particularly in an era of increased biologic prescribing. We aimed to analyse these trends in a population‐based IBD cohort over the last 10 years....

Descripción completa

Detalles Bibliográficos
Autores principales:	Lyons, Mathew, Derikx, Lauranne A. A. P., Fulforth, James, McCall, Sophie, Plevris, Nikolas, Jenkinson, Philip W., Kirkwood, Kathryn, Siakavellas, Spyros, Lucaciu, Laura, Constantine‐Cooke, Nathan, Arnott, Ian D., Henderson, Paul, Russell, Richard K., Wilson, David C., Lees, Charlie W., Jones, Gareth‐Rhys
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Emergency Hospitalisation for IBD
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9314623/ https://www.ncbi.nlm.nih.gov/pubmed/35301734 http://dx.doi.org/10.1111/apt.16867

Ejemplares similares

IBD prevalence in Lothian, Scotland, derived by capture–recapture methodology
por: Jones, Gareth-Rhys, et al.
Publicado: (2019)

Real-world experience with tofacitinib in ulcerative colitis: a systematic review and meta-analysis
por: Lucaciu, Laura A., et al.
Publicado: (2021)

Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts
por: Derikx, Lauranne A A P, et al.
Publicado: (2021)

IBD LIVE Case Series–Case 2: Previous Cancer in a Patient with Crohn's Disease: Is It Appropriate to Use Biologics and Immunosuppressants for IBD Treatment?
por: Le, Peter N., et al.
Publicado: (2015)

Going Viral: Management of IBD in the Era of the COVID-19 Pandemic
por: Gutin, Liat S., et al.
Publicado: (2020)

Development of the IBD Disk: A Visual Self-administered Tool for Assessing Disability in Inflammatory Bowel Diseases
por: Ghosh, Subrata, et al.
Publicado: (2017)

Multiple infliximab biosimilar switches appear to be safe and effective in a real‐world inflammatory bowel disease cohort
por: Gros, Beatriz, et al.
Publicado: (2023)

IBD barriers across the continents – East Asia
por: Mak, Joyce Wing Yan, et al.
Publicado: (2023)

IBD barriers across the continents: a continent-specific analysis – Australasia
por: Elford, Alexander T., et al.
Publicado: (2023)

Challenges in the diagnosis and management of IBD: a sub-Saharan African perspective
por: Watermeyer, Gill, et al.
Publicado: (2023)

IBD barriers across the continents: a continent-specific analysis: Latin America
por: Queiroz, Natália Sousa Freitas, et al.
Publicado: (2023)

Inflammatory bowel disease patient‐reported quality assessment should drive service improvement: a national survey of UK IBD units and patients
por: Hawthorne, A. Barney, et al.
Publicado: (2022)

Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease
por: Kennedy, Nicholas A., et al.
Publicado: (2019)

A Mobile Infliximab Dosing Calculator for Therapy Optimization in Inflammatory Bowel Disease
por: Piester, Travis, et al.
Publicado: (2018)

Mendelian Disease Associations Reveal Novel Insights into Inflammatory Bowel Disease
por: Han, Lichy, et al.
Publicado: (2018)

The Association Between Sustained Poor Quality of Life and Future Opioid Use in Inflammatory Bowel Disease
por: Anderson, Alyce, et al.
Publicado: (2018)

Incidence, prevalence and clinical outcome of anaemia in inflammatory bowel disease: a population‐based cohort study
por: Eriksson, Carl, et al.
Publicado: (2018)

Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis
por: Mahadevan, Uma, et al.
Publicado: (2018)

Infliximab for Crohn’s Disease: More Than 13 Years of Real-world Experience
por: Lichtenstein, Gary R, et al.
Publicado: (2018)

What Is the Risk of Progressive Multifocal Leukoencephalopathy in Patients With Ulcerative Colitis or Crohn’s Disease Treated With Vedolizumab?
por: Card, Timothy, et al.
Publicado: (2018)

Communication Between Physicians and Patients with Ulcerative Colitis: Reflections and Insights from a Qualitative Study of In-Office Patient–Physician Visits
por: Rubin, David T., et al.
Publicado: (2017)

Risk of dementia in patients with inflammatory bowel disease: a Danish population‐based study
por: Rønnow Sand, Jakob, et al.
Publicado: (2022)

Thiopurine withdrawal during sustained clinical remission in inflammatory bowel disease: relapse and recapture rates, with predictive factors in 237 patients
por: Kennedy, N A, et al.
Publicado: (2014)

Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients
por: Lam, Angela Y., et al.
Publicado: (2020)

Opportunistic Knocks: A Gardener with Ulcerative Colitis and New Pulmonary Nodules
por: Canakis, Andrew, et al.
Publicado: (2023)

Lower Extremity Palpable Purpura in a Patient with Quiescent Inflammatory Bowel Disease
por: Darlington, Kimberly, et al.
Publicado: (2023)

Hepatitis E virus is the leading cause of acute viral hepatitis in Lothian, Scotland
por: Kokki, I., et al.
Publicado: (2015)

The risk of unexpected hospital admissions and primary care visits after an elective day‐case gastroscopy: a cohort study within England
por: Crooks, Colin J., et al.
Publicado: (2022)

Effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in patients with Crohn's disease or ulcerative colitis who had failed conventional therapy
por: Colombel, J.‐F., et al.
Publicado: (2016)

Classic drugs in the time of new drugs: real‐world, long‐term outcomes of thiopurine monotherapy in 1016 patients with inflammatory bowel disease
por: Rezazadeh Ardabili, Ashkan, et al.
Publicado: (2022)

The knowledge and skills needed to perform intestinal ultrasound for inflammatory bowel diseases—an international Delphi consensus survey
por: Madsen, Gorm Roager, et al.
Publicado: (2022)

Minor impact on fertility in men with inflammatory bowel disease: A National Cohort Study from Sweden
por: Druvefors, Emma, et al.
Publicado: (2022)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Antidepressant medication use in Inflammatory Bowel Disease: a nationally representative population‐based study
por: Jayasooriya, Nishani, et al.
Publicado: (2022)

Implications for sequencing of biologic therapy and choice of second anti‐TNF in patients with inflammatory bowel disease: results from the IMmunogenicity to Second Anti‐TNF therapy (IMSAT) therapeutic drug monitoring study
por: Chanchlani, Neil, et al.
Publicado: (2022)

DNA methylation outlier burden, health, and ageing in Generation Scotland and the Lothian Birth Cohorts of 1921 and 1936
por: Seeboth, Anne, et al.
Publicado: (2020)

Positioning biologics in the treatment of IBD: A practical guide – Which mechanism of action for whom?
por: Juillerat, Pascal, et al.
Publicado: (2022)

The management of iron deficiency in inflammatory bowel disease – an online tool developed by the RAND/UCLA appropriateness method
por: Reinisch, W, et al.
Publicado: (2013)

Norman Veitch Lothian
Publicado: (1925)

Robert Bain Lothian
Publicado: (1922)

Cannot write session to /tmp/vufind_sessions/sess_hqsb06dpuktapglbbn9dfqq8l6